Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anhui Univ. of Chinese Medicine HDAC6 compound 59
- Development stage
- Unknown
- Lead developer
- Anhui University of Chinese Medicine
01
Overview
Anhui Univ. of Chinese Medicine HDAC6 compound 59: sourced facts only. name: "SAR study culminated in the discovery of compound 59, which exhibited remarkable inhibitory activity against both PI3Kδ (IC50 = 2.3 nM) and HDAC6 (IC50 = 13 nM), along with acceptable subtype specificity." [PMID:36182802]; target: "SAR study culminated in the discovery of compound 59, which exhibited remarkable inhibitory activity against both PI3Kδ (IC50 = 2.3 nM) and HDAC6 (IC50 = 13 nM), along with acceptable subtype specificity." [PMID:36182802]; developer: "School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China." [PMID:36182802]
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on Anhui Univ. of Chinese Medicine HDAC6 compound 59.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anhui Univ. of Chinese Medicine HDAC6 compound 59.